In drug discovery, the headlines go to finding molecules—but 90% of candidates fail during process chemistry: the hard, expensive work of scaling synthesis. Most drug IP today simply never reaches patients. Ai.Qimia solves this. Our physics-informed AI will model real lab conditions—temperature, solvents, catalysts—and predict successful synthesis scale-up, learning even from negative experimental data (a major blind spot today). We’re launching from a decade of proprietary software and rich experimental data. Our initial SaaS platform will serve biotechs, CROs, and chemistry teams—building revenue and critical data assets from Day 1. Sectors Artificial intelligence, Enterprise software, Pharmaceuticals Location Lausanne, Switzerland Stage Sign in to view details Markets Sign in to view details Customer model Sign in to view details Contact Sign in to view details Social media